Elenco degli articoli con argomento «ustekinumab»
Dermatologia18 apr 2022
Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab
Biological therapies are valuable treatments for severe psoriasis. Children aged under 12 years are underrepresented in therapeutic trials for these drugs.
14 set 2020
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab
Is the risk of severe cardiovascular events increased after the initiation of treatment with the anti–interleukin 12/23p40 (IL-12/23p40) monoclonal antibody ustekinumab?
15 giu 2020
Treatment of erythrodermic psoriasis with biologics
A systematic review
29 ott 2019
Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study.
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.
23 apr 2019
Psoriasi: grazie alle nuove terapie miglioramenti fino al 90% in poche settimane
Con l’arrivo dei nuovi farmaci, oggi il trattamento di questa malattia infiammatoria è in grado di restituire ai pazienti una pelle pulita senza effetti collaterali pesanti. Ma è importante fare riferimento al dermatologo per una diagnosi precoce. Al via una campagna educativa della Società Italiana di Dermatologia
24 ott 2017
Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis
More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores
10 ott 2017
Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis
Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy
13 mar 2017
Ixekizumab Superior to Ustekinumab for Treating Psoriasis
Patients with psoriasis treated with the targeted agent ixekizumab appear to have better outcomes at 24 weeks than those treated with ustekinumab, according to the 24-week data of the ongoing IXORA-S trial presented at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
11 ott 2016
Psoriasi, farmaci biologici a tutti i malati?
Se somministrare o meno i nuovi farmaci biologici a tutti i malati di psoriasi è la domanda che ha «tenuto banco» al congresso annuale dell'Accademia Europea di Dermatologia (EADV) che si è da poco concluso a Vienna.
19 giu 2015
Ustekinumab Effective in Treatment of Psoriatic Arthritis With Spondylitis
Ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody approved for the treatment of psoriatic arthritis, shows significant improvement in patients with psoriatric arthritis who also have spondylitis and peripheral joint involvement